Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 548 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Training Cancer Researchers: A Conversation with Dr. Oliver Bogler April 1, 2020 ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People October 18, 2023 Load more HOT NEWS Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... Easing Concerns about Giving Research Study Participants Their Genetic Test Results Cómo prepararse para su exploración por TEP-TC FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who...
